Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
Zydus Lifesciences Limited (Formerly known ... Oxemia. It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Nippon India Small Cap Fund (B) 467.76 29,95,942 0.92 Nippon India Small Cap Fund (IDCW) 467.76 29,95,942 0.92 Nippon India Small Cap Fund (G) 467.76 29,95,942 0.92 ...
Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...
Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 10,611.30 Crore) operating in FMCG sector. Zydus Wellness Ltd. key Products/Revenue Segments include ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
3 Year 150.57% 150.71% 34.23% 36.41% ...
The Quarterly Results page of Zydus Lifesciences Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results